Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Equity Average (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Equity Average for 15 consecutive years, with $535.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 333.7% year-over-year to $535.9 million, compared with a TTM value of $535.9 million through Dec 2025, up 333.7%, and an annual FY2025 reading of $347.2 million, up 45.22% over the prior year.
  • Equity Average was $535.9 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $511.6 million in the prior quarter.
  • Across five years, Equity Average topped out at $602.0 million in Q2 2025 and bottomed at $123.6 million in Q4 2024.
  • Average Equity Average over 5 years is $400.7 million, with a median of $420.0 million recorded in 2021.
  • The sharpest move saw Equity Average crashed 46.38% in 2024, then skyrocketed 333.7% in 2025.
  • Year by year, Equity Average stood at $390.7 million in 2021, then increased by 4.27% to $407.4 million in 2022, then tumbled by 43.43% to $230.4 million in 2023, then plummeted by 46.38% to $123.6 million in 2024, then surged by 333.7% to $535.9 million in 2025.
  • Business Quant data shows Equity Average for ARWR at $535.9 million in Q4 2025, $511.6 million in Q3 2025, and $602.0 million in Q2 2025.